VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF(165) and antiangiogenic VEGF(165)b. Using iso...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Varey, A H R, Rennel, E S, Qiu, Y, Bevan, H S, Perrin, R M, Raffy, S, Dixon, A R, Paraskeva, C, Zaccheo, O, Hassan, A B, Harper, S J, Bates, D O
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2008
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361696/
https://ncbi.nlm.nih.gov/pubmed/18349829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604308
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars